CompletedPhase 2NCT02666768

ACTIMMUNE in Intermediate Osteopetrosis

Studying Albers-Schönberg osteopetrosis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Principal Investigator: Lynda E Polgreen, MD, MS, MD
Los Angeles BioMedical Research Center at Harbor-UCLA
Intervention: Interferon gamma-1b(drug)
Enrollment: 5 enrolled
Eligibility: 1 years · All sexes
Timeline: 2016 – 2019

Study locations (2)

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
University of Minnesota, Minneapolis, Minnesota, United States

Collaborators

University of Minnesota · Horizon Pharma Ireland, Ltd., Dublin Ireland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02666768 on ClinicalTrials.gov

← Back to all trials